Targeting novel regulated cell death: Ferroptosis, pyroptosis and necroptosis in anti‐PD ‐1/ PD‐L1 cancer immunotherapy
Cell Proliferation · 2024-08 · 57 (8)
DOI: 10.1111/cpr.13644 ↗At a glance
Übersichtsarbeit in Cell Proliferation, published online on 2024-04-09. Written by Li Yu and 5 co-authors. Institution: Health Science Center, Yangtze University, Jingzhou, Hubei, China. Major MEDLINE topics: Pyroptosis, Ferroptosis, Neoplasms, Necroptosis. Cited 75 times so far (Crossref); 135 references. The full text is freely available (open access, CC BY 4.0). Funded by: Belt and Road Initiative Innovative Talent Exchange Foreign Expert Project, Singapore Ministry of Health's National Medical Research Council, Joint NCIS and NUS Cancer Pro-gram Seed Funding Grants.
Abstract (original language)
Chemotherapy, radiotherapy, and immunotherapy represent key tumour treatment strategies. Notably, immune checkpoint inhibitors (ICIs), particularly anti‐programmed cell death 1 (PD1) and anti‐programmed cell death ligand 1 (PD‐L1), have shown clinical efficacy in clinical tumour immunotherapy. However, the limited effectiveness of ICIs is evident due to many cancers exhibiting poor responses to this treatment. An emerging avenue involves triggering non‐apoptotic regulated cell death (RCD), a significant mechanism driving cancer cell death in diverse cancer treatments. Recent research demonstrates that combining RCD inducers with ICIs significantly enhances their antitumor efficacy across various cancer types. The use of anti‐PD‐1/PD‐L1 immunotherapy activates CD8 + T cells, prompting the initiation of novel RCD forms, such as ferroptosis, pyroptosis, and necroptosis. However, the functions and mechanisms of non‐apoptotic RCD in anti‐PD1/PD‐L1 therapy remain insufficiently explored. This review summarises the emerging roles of ferroptosis, pyroptosis, and necroptosis in anti‐PD1/PD‐L1 immunotherapy. It emphasises the synergy between nanomaterials and PD‐1/PD‐L1 inhibitors to induce non‐apoptotic RCD in different cancer types. Furthermore, targeting cell death signalling pathways in combination with anti‐PD1/PD‐L1 therapies holds promise as a prospective immunotherapy strategy for tumour treatment.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Health Science Center, Yangtze University, Jingzhou, Hubei, China.
- Department of Urology, Jingzhou Central Hospital, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, Hubei, China.
- Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
- NUS Centre for Cancer Research (N2CR), National University of Singapore, Singapore, Singapore.
ORCID profiles: Li Yu, Gautam Sethi, Zhaowu Ma
Funding
- Belt and Road Initiative Innovative Talent Exchange Foreign Expert Project
- Singapore Ministry of Health's National Medical Research Council
- Joint NCIS and NUS Cancer Pro-gram Seed Funding Grants
Cite
APA
Yu, L., Huang, K., Liao, Y., Wang, L., Sethi, G., & Ma, Z. (2024). Targeting novel regulated cell death: Ferroptosis, pyroptosis and necroptosis in anti‐PD ‐1/ PD‐L1 cancer immunotherapy. Cell Proliferation, 57(8). https://doi.org/10.1111/cpr.13644
Vancouver
Yu L, Huang K, Liao Y, Wang L, Sethi G, Ma Z. Targeting novel regulated cell death: Ferroptosis, pyroptosis and necroptosis in anti‐PD ‐1/ PD‐L1 cancer immunotherapy. Cell Proliferation. 2024;57(8). doi:10.1111/cpr.13644
BibTeX
@article{Yu2024,
author = {Yu, Li and Huang, Ke and Liao, Yixiang and Wang, Lingzhi and Sethi, Gautam and Ma, Zhaowu},
title = {Targeting novel regulated cell death: Ferroptosis, pyroptosis and necroptosis in anti‐PD ‐1/ PD‐L1 cancer immunotherapy},
journal = {Cell Proliferation},
year = {2024},
volume = {57},
number = {8},
doi = {10.1111/cpr.13644}
}
EUVIMED